2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 635

Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Abstract Number: 850

Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Abstract Number: 1893

Eliciting Prescribing Choices of Anti-Tumour Necrosis Factor Therapy From Rheumatology Trainees
Abstract Number: 1865

Emotional Pain and Catastrophizing Influence Quality of Life in Fibromyalgia
Abstract Number: 863

Employment of a Needs Assessment Survey to Shape a Novel Web-Based Pediatric Rheumatology Curriculum for Primary Care Providers
Abstract Number: 1059

Endogenous Complement Factor H Plays an Important Role in Controlling Immune Complex-Induced Inflammatory Arthritis
Abstract Number: 699

Endothelial Dysfunction and Vascular Stiffness in Early Diffuse Systemic Sclerosis
Abstract Number: 623

Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Abstract Number: 859

Endothelin-1 (ET-1) Induces Extracellular Matrix Protein Production by Human Temporal Artery Derived Myointimal Cells. A Mechanism Potentially Leading to Intimal Hyperplasia and Vascular Occlusion in Giant-Cell Arteritis
Abstract Number: 1472

Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis
Abstract Number: 1644

Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Abstract Number: 2291

Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis
Abstract Number: 847

Enhanced ROCK Activation in Patients with Systemic Lupus Erythematosus
Abstract Number: 2310

Enhancement of CRACM1 Expression in Functionally Aberrant Naïve CD4⁺ T Cells in Active Rheumatoid Arthritis
Abstract Number: 2042

Enhancing Shared Decision-Making in Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].